We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

174 hedge funds and large institutions have $385M invested in Allogene Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 64 increasing their positions, 43 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 16

49% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 43

24% more call options, than puts

Call options by funds: $392K | Put options by funds: $317K

8% more funds holding

Funds holding: 161 → 174 (+13)

1.52% more ownership

Funds ownership: 77.6% → 79.12% (+1.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

34% less capital invested

Capital invested by funds: $586M → $385M (-$201M)

Holders
174
Holders Change
+13
Holders Change %
+8.07%
% of All Funds
2.51%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
30
Increased
64
Reduced
43
Closed
16
Calls
$392K
Puts
$317K
Net Calls
+$75K
Net Calls Change
-$947K

Top Buyers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
+$20.3M
2
BlackRock
BlackRock
New York
+$20M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$17.4M
4
PA
Perceptive Advisors
New York
+$8.04M
5
LCM
Lynx1 Capital Management
Puerto Rico
+$6.57M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$4.47M
2
OCA
Octagon Capital Advisors
New York
-$3.22M
3
JP Morgan Chase
JP Morgan Chase
New York
-$3.12M
4
ZIM
Zacks Investment Management
Illinois
-$2.06M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$2.75M +$944K +319,925 +37%
Northern Trust
27
Northern Trust
Illinois
$2.42M +$198K +67,038 +7%
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$2.05M +$2.59M +878,955 New
GCP
29
GSA Capital Partners
United Kingdom
$1.95M +$2.46M +835,342 New
TD Asset Management
30
TD Asset Management
Ontario, Canada
$1.86M +$1.07M +361,904 +83%
SCM
31
Superstring Capital Management
New York
$1.61M +$498K +168,663 +32%
Nordea Investment Management
32
Nordea Investment Management
Sweden
$1.48M -$317K -107,454 -14%
Jane Street
33
Jane Street
New York
$1.41M +$1.5M +507,464 +520%
DCM
34
DAFNA Capital Management
California
$1.41M +$1.79M +605,100 New
Rafferty Asset Management
35
Rafferty Asset Management
New York
$1.36M -$1.2M -405,863 -41%
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.12M +$585K +198,231 +70%
CANY
37
Caxton Associates (New York)
New York
$1.09M +$103K +34,924 +8%
PCIG
38
Partners Capital Investment Group
Massachusetts
$1.07M +$1.07M +361,597 +388%
Bank of America
39
Bank of America
North Carolina
$1.01M +$83.5K +28,321 +7%
Cerity Partners
40
Cerity Partners
New York
$1.01M +$23.5K +7,981 +2%
SFI
41
Susquehanna Fundamental Investments
Pennsylvania
$976K +$390K +132,291 +46%
CBA
42
Coastal Bridge Advisors
Connecticut
$948K – – –
Bank of New York Mellon
43
Bank of New York Mellon
New York
$844K +$182K +61,811 +21%
Ameriprise
44
Ameriprise
Minnesota
$788K +$440K +149,005 +79%
UBS Group
45
UBS Group
Switzerland
$700K -$646K -218,880 -42%
ECM
46
ExodusPoint Capital Management
New York
$678K +$378K +128,091 +79%
Swiss National Bank
47
Swiss National Bank
Switzerland
$669K +$213K +72,200 +34%
UBS AM
48
UBS AM
Illinois
$622K +$285K +96,497 +57%
Mirae Asset Global ETFs Holdings
49
Mirae Asset Global ETFs Holdings
Hong Kong
$618K +$780K +264,329 New
Mitsubishi UFJ Asset Management
50
Mitsubishi UFJ Asset Management
Japan
$573K +$83.9K +28,439 +13%
1
2
3 4 5

ALLO Hedge Fund Activity: Q2 2024 in Review

174 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2024, worth a combined $385M — down 34% from $586M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new ALLO positions and 16 closed out — a net gain of 14 holders — while 64 added to existing stakes and 43 trimmed.

The largest buyer was Capital World Investors, opening a new position worth an estimated $20.3M. The largest seller was State Street, cutting an estimated $4.47M.

  • 174 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2024, up from 161 in Q1 2024.
  • Funds reported $385M of Allogene Therapeutics stock for Q2 2024, down 34% quarter-over-quarter.
  • 30 funds opened new Allogene Therapeutics positions in Q2 2024 and 16 closed out, a net change of +14 holders.
  • The largest Allogene Therapeutics buyer in Q2 2024 was Capital World Investors, an estimated $20.3M added.
  • The largest Allogene Therapeutics seller in Q2 2024 was State Street, an estimated $4.47M sold.

Based on aggregated 13F filings for Q2 2024.